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Abstract
Background: Over the last decade, nosocomial infections due to Acinetobacter baumannii have
been described with an increasing trend towards multidrug resistance, mostly in intensive care
units. The aim of the present study was to determine the clonal relatedness of clinical isolates and
to elucidate the genetic basis of imipenem resistance.
Methods: A. baumannii isolates (n = 83) originated from two hospital settings in central Ohio were
used in this study. Pulsed-field gel electrophoresis genotyping and antimicrobial susceptibility
testing for clinically relevant antimicrobials were performed. Resistance determinants were
characterized by using different phenotypic (accumulation assay for efflux) and genotypic (PCR,
DNA sequencing, plasmid analysis and electroporation) approaches.
Results: The isolates were predominantly multidrug resistant (>79.5%) and comprised of thirteen
unique pulsotypes, with genotype VII circulating in both hospitals. The presence of blaOXA-23 in 13%
(11/83) and ISAba1 linked blaOXA-66 in 79.5% (66/83) of clinical isolates was associated with high level
imipenem resistance. In this set of OXA producing isolates, multidrug resistance was bestowed by
blaADC-25, class 1 integron-borne aminoglycoside modifying enzymes, presence of sense mutations
in gyrA/parC and involvement of active efflux (with evidence for the presence of adeB efflux gene).
Conclusion: This study underscores the major role of carbapenem-hydrolyzing class D β-
lactamases, and in particular the acquired OXA-23, in the dissemination of imipenem-resistant A.
baumannii. The co-occurrence of additional resistance determinant could also be a significant
threat.
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Acinetobacter baumannii is a rapidly emerging nosocomial
pathogen and causes severe infections that include bacter-
emia, pneumonia, meningitis, urinary tract and wound
infections [1]. It has now become a major cause of hospi-
tal-acquired infections worldwide due to its remarkable
propensity to rapidly acquire resistance determinants to a
wide range of antibacterial agents [2]. Of note, increasing
resistance to carbapenems has been observed worldwide
in the past decade [3]. Carbapenemase production is the
most described mechanism of resistance to carbapenems
[4]. The carbapenemases in A. baumannii have belonged
to the blaOXA-23-, blaOXA-24-, and blaOXA-58- type class D fam-
ily of serine β-lactamases and IMP/VIM class B metallo-β-
lactamases [3,4]. The upstream of OXA type class D car-
bapenemases in Acinetobacter is often associated with
insertion sequence (IS), ISAba1 and other IS may modu-
late the expression and transfer of OXA-type carbapene-
mase genes [5-10]. IS are mobile genetic elements known
to affect the evolutionary pattern of bacterial genomes.
Upon integration, IS elements may cause DNA insertions/
deletions, chromosomal rearrangement, modulate the
expression of neighbouring genes and, thereby, influence
the phenotype of a bacterium [11].
Numerous outbreaks caused by multidrug-resistant
(MDR) A. baumannii from different parts of United States
are appearing very rapidly [12-16]. One of the most
poignant instances is the widespread prevalence of MDR
A. baumannii among personnel returning from military
operations in Iraq and Afghanistan [17]. The Infectious
Diseases Society of America (IDSA) identified A. bauman-
nii among the top seven pathogens threatening our
healthcare-delivery system and as a crucial example of
unmet medical need [18].
Our phenotypic analysis clearly demonstrated that A. bau-
mannii isolates obtained from different hospitals in cen-
tral Ohio were resistant to all clinically significant
antibiotics, including carbapenems (imipenem). The aim
of the present study was to determine the clonal related-
ness among clinical isolates and the genetic basis for imi-
penem resistance. Molecular determinants enabling the
imipenem resistant strains to exhibit co-resistance to
aminoglycosides and fluoroquinolones from this geo-
graphical region were delineated.
Methods
Study population
A. baumannii isolates (n = 83) that originated from two
sources were investigated. They consisted of isolates from
The Ohio State University Medical Center (referred as
MC) (n = 47) and other central Ohio hospitals retrieved
from the Ohio Department of Health (referred as ODH)
(n = 36) collected during 2005–2007 time period. These
isolates were obtained from different Intensive Care Units
(ICU) and non-ICUs in the hospitals. The selection crite-
ria of these strains were based on the heterogeneity in
their properties such as, geographic origin, time of isola-
tion, levels of resistance to carbapenems, aminoglycosides
and fluoroquinolones, thus excluding multiple isolates of
the same strain from one locality. Forty-seven isolates of
MC were originally isolated from aspirated sputum
(24%), BAL (17%), bronchial wash (16%) and other sys-
tems including blood (26%), wound (2%) and urinary
infections (15%). Thirty-six isolates from ODH were
obtained from bronchial wash (37%), sputum (33%),
blood (8%), BAL (12%) and remaining 10% from urine
and wound. The isolates were obtained from patients
belonging to different age groups: 60–90 years (n = 54),
20–50 years (n = 28) and one isolate from a 15-year-old.
No additional individual patient data was retrieved as it
was beyond the scope of this investigation. Institutional
Review Board exemption was obtained prior to retrieval of
the isolates from the pathogen bank.
Bacterial isolation and identification
The 83 A. baumannii clinical isolates were identified by
using the Vitek 2® automated instrument ID system
(BioMérieux, Marcy l'Etoile, France), API 20NE system
(BioMerieux, Inc) and NUC 45 Identification Panel
(MicroScanR, Siemen's Healthcare, Sacramento, CA, USA)
and sequencing of the gyrA house keeping gene, as
described previously [19].
Minimum Inhibitory Concentration (MIC)
Susceptibilities of A.baumannii isolates to imipenem,
ceftazidime, amikacin, streptomycin, gentamicin, kan-
amycin, tetracycline, ciprofloxacin and nalidixic acid were
tested using broth dilution technique. Multidrug resist-
ance was defined in this analysis as resistance to three or
more representatives of the following classes of antibiot-
ics: quinolones (ciprofloxacin and nalidixic acid),
extended-spectrum cephalosporins (ceftazidime),
aminoglycosides (amikacin, streptomycin, gentamicin,
kanamycin), and carbapenems (imipenem). Interpreta-
tion was done as per the criteria approved by the Clinical
and Laboratory Standards Institute CLSI [20]. E. coli ATCC
25922 was used as a reference strain (control) as recom-
mended.
Pulsed-field gel electrophoresis (PFGE) genotyping
PFGE was performed according to the Centers for Disease
Control and Prevention Pulse Net protocol [21] with
minor modifications. Fingerprint images were analyzed
by Bionumerics software V. 4.61 (Applied Maths NV, Bel-
gium) using dice similarity index for cluster analysis and
the unweighted pair group average (UPGMA) for tree
building. All isolates with PFGE banding patterns with a
similarity index >75% were grouped within the same clus-Page 2 of 10
(page number not for citation purposes)
Annals of Clinical Microbiology and Antimicrobials 2009, 8:21 http://www.ann-clinmicrob.com/content/8/1/21ter. Banding patterns were compared with 3.0% optimiza-
tion and 2.5% band position tolerance.
PCR amplifications and sequence analyses
Genomic DNA was extracted using DNeasy Tissue kit
(Qiagen; Valencia, CA, USA). PCR for evaluating the pres-
ence of 13 different β-lactamases, ISAba1, IS1133, class 1
integrons and its variable region, int2, int3, aphA6, qnrA1–
6, qnrB1–6 and qnrS1–2[22], tet(A), tet(B) [23], quinolone
resistance determining region (QRDR) of gyrA, parC, adeB,
adeR and adeS genes were carried out using specific prim-
ers (Table 1). All amplicons were sequenced bidirection-
ally using CEQ 8000 (Beckman Coulter Instruments Inc.,
Palo Alto, CA) capillary electrophoresis system and ana-
lyzed by BLAST at http://www.ncbi.nlm.nih.gov. To deter-
mine the location and orientation of the insertion
sequence (IS) element, combination primers specific to
both ISAba1 and blaOXA-66 or blaADC-25 were used [24,25].
Plasmid analysis
Plasmid DNA was isolated using alkaline lysis method as
described before [26]. Escherichia coli JM109 electrocom-
petent cells were transformed with 30 ng of plasmid prep-
arations and were screened on LB plates (Difco, Becton-
Dickinson, Sparks, MD) containing different antibiotics,
(Sigma, St. Louis, MO): amikacin, streptomycin, gen-
tamicin, kanamycin (10 μg/ml respectively), imipenem (1
μg/ml), ciprofloxacin (1 μg/ml), nalidixic acid (30 μg/ml)
Table 1: Primers used for PCR amplification
Primer sequence (5' to 3') Reference
Target gene(s) Forward Reverse Size of amplicon
blaTEM-1 GCACGAGTGGGTTACATCGA GGTCCTCCGATCGTTGTCAG 310 14
blaPER-1 ATGAATGTCATTATAAAAG TTGGGCTTAGGGCAG 927 14
blaIMP alleles1-21 GTTTATGTTCATACWTCG GGTTTAAYAAAACAACCAC 432 14
blaVIM alleles TTTGGTCGCATATCGCAACG CCATTCAGCCAGATCGGCAT 500 14
blaGIM ATATTACTTGTAGCGTTGCCAGC TTAATCAGCCGACGCTTCAG 729 14
blaSHV ATGCGTTATATTCGCCTGTG TGCTTTGTTATTCGGGCCAA 753 14
blaSIM ATGAGAACTTTATTGATTTT TTAATTAATGAGCGGCGGTT 741 This study
blaCTX-M ATGATGACTCAGAGCATTCGCCGCT TCAGAAACCGTGGGTTACGATTTTCG 876 14
blaADC ATGCGATTTAAAAAAATTTCTTGT TGGAATACGTTTATTGGTTAACATGA 1081 14
OXA-23-like TCTGGTTGTACGGTTCAGC AGTCTTTCCAAAAATTTTG 606 14
OXA-24-like ATGAAAAAATTTATACTTCC TTAAATGATTCCAAGATTTTC 828 14
OXA-51-like ACAGAARTATTTAAGTGGG GGTCTACAKCCMWTCCCCA 880 14
blaOXA-58 ATGAAATTATTAAAAATATTGAGTTTA
G
TTATAAATAATGAAAAACACCCAAC 843 14
ISAba1 ATGCAGCGCTTCTTTGCAGG AATGATTGGTGACAATGAAG 393 14
IS1133 ATGACACATCTCAATGAGTTATAT TTAACACGAATGCAGAAGTTGATG 543 14
ISAb-F1/OXA/IS-R AGTTGCACTTGGTCGAATGAA CCATAGCTTTGTTGAGTTTGG 540 22
ISAb-F2/OXA/IS-R TTGAAAATACGCGCTTGACAGA CCATAGCTTTGTTGAGTTTGG 1104 22
ISAb-F3/OXA/IS-R CTCTGTACACGACAAATTTCAC CCATAGCTTTGTTGAGTTTGG 1384 22
ISAba1-ampC-UP GACCTGCAAAGAAGCGCTGCATA TTGGTTCTTTTAAACCATATACC 1502 This study
intI1 5'CS GACGATGCGTGGAGACC CTTGCTGCTTGGATGCC 300 25
intI1 3'CS ATCGCAATAGTTGGCGAAGT GCAAGGCGGAAACCCGCC 800 25
Variable region GGCATCCAAGCAGCAAGC AAGCAGACTTGACCTGAT Variable 25
intI2 ACGATGCCTGCTTTTTGTACGGCTGC CCGTCTATCCTGCTTGCACGATGCA 962 This study
intI3 TCAGCCGGGCGACAAGTGCAAGGCC
A
ATGAACAGGTATAACAGAAAT 1041 This study
aphA6 ATGGAATTGCCCAATATTATTC TCAATTCAATTCATCAAGTTTTA 780 14
tet A GCGCGATCTGGTTCACTCG AGTCGACAGYRGCGCCGGC 164 36
tet B TACGTGAATTTATTGCTTCGG ATACAGCATCCAAAGCGCAC 206 36
qnrA1 to qnrA6 AGAGGATTTCTCACGCCAGG TGCCAGGCACAGATCTTGAC 661 37
qnrB1 to qnrB6 GGMATHGAAATTCGCCACTG TTTGCYGYYCGCCAGTCGAA 562 37
qnrS1 to qnrS2 GCAAGTTCATTGAACAGGGT TCTAAACCGTCGAGTTCGGCG 605 37
gyrA (QRDR) AAATCTGCCCGTGTCGTTGGT GCCATACCTACGGCGATACC 285 14
parC (QRDR) AAAAATCAGCGCGTACAGTG CGAGAGTTTGGCTTCGGTAT 276 14
adeB GGATTATGGCGACAGAAGGA AATACTGCCGCCAATACCAG 981 This study
adeR ATGTTTGATCATTCTTTTTCTTTTG TTAATTAACATTTGAAATATG 687 14
adeS TTCAACAAGAAGATTGGACC CTTGCTCAATACGACGG 114 28
a Y = C or T; M = A or C; R = A or G; W = A or T; K = G or T; H = A or C or T.
b QRDR, quinolone resistance-determining region.Page 3 of 10
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restreaked on identical plates for confirmation.
In vitro studies to elucidate the occurrence of active efflux
The accumulation of ciprofloxacin was examined as
described previously [27]. The efflux pump inhibitors
used in this study were carbonyl cyanide m-chlorophenyl-
hydrazone (CCCP), verapamil and reserpine, (Sigma, St.
Louis, MO); to a final concentration of 25 μg/ml. The
growth inhibition assay was done as described previously
with minor modifications [28]. A. baumannii cultures at
mid log phase (OD 600nm = 0.2) were inoculated into LB
broth containing antimicrobials at different concentra-
tions either alone or with inhibitor. The extent of growth
inhibition was analyzed by measuring the absorbance at
600 nm (OD 600nm) after 6 hrs of incubation at 37°C. All
data from the in vitro kinetics and flourimetric assay are
presented as means ± the standard error of the mean and
calculation of the standard deviation was performed in
Excel (Microsoft, USA). The statistical significance was
determined using the paired Student's t-test. P values of <
0.05 were considered significant.
Accession numbers
The sequences of aadB, aadB-aadA2, aacC1-orfX-orfX'-
aadA1, aacA4-catB8- aadA2, blaOXA-66, blaTEM-1, blaADC-25,
aphA6, ISAba1, blaOXA-23, QRDR of gyrA and parC genes
obtained in this study were deposited in the GenBank
database under the following accession numbers:
EU977565, EU977566, EU977567, EU977568,
EU977569, EU977570, EU977571, EU977572,
EU977573, EU977574, EU977575 and EU977576 respec-
tively.
Results
Antimicrobial susceptibility and genotypic diversity
In this study, about 79.5% (66/83) were multi-drug resist-
ant (MDR). Among these, 62 were resistant to ceftazidime
and 66 were resistant to imipenem. The imipenem resist-
ant isolates (66/83) were also resistant to kanamycin,
amikacin, gentamicin, streptomycin, tetracycline, cipro-
floxacin and nalidixic acid. Overall, 7% (6/83) were
found resistant only to chloramphenicol and remaining
14.5% (12/83) isolates were pan-susceptible (See Addi-
tional file 1).
To determine the extent of genotypic diversity among the
MDR A. baumannii, PFGE was conducted and the isolates
were clustered into thirteen major genotypes (I to XIII) at
75% genotypic similarity threshold. Profiles of randomly
selected isolates (n = 31) are depicted in Figure 1. Though
their genotypes were diverse, majority of the isolates
exhibited increased resistance to β-lactams, aminoglyco-
sides and quinolones. Genotype VII was found as the
most common cluster type (28/83) that was found circu-
lating in hospitals regardless of origin: 16 isolates from
MC (19%) and 12 from ODH (14%).
Molecular determinants for β-lactam resistance
Eleven imipenem resistant isolates (13%) contained the
acquired carbapenem hydrolyzing class D β-lactamase
(CHDLs) gene blaOXA-23 [GenBank: EU977574] (See Addi-
tional file 1). The other CHDLs including blaOXA-24 and
blaOXA-58 like genes could not be identified in this study.
Sixty-six imipenem resistant isolates (79.5%) carried
ISAba1 genetic element preceding the naturally occurring
carbapenemase blaOXA-66, a blaOXA-51 like gene [GenBank:
EU977573, EU977569] (See Additional file 1). However
IS1133 was not found in this collection.
The cephalosporinase blaADC-25 was detected in 62 ceftazi-
dime resistant isolates and PCR mapping indicated that
ISAba1 was not present upstream to the cephalosporinase
identified in this study [GenBank: EU977571] (See Addi-
tional file 1).
The class A β-lactamase blaTEM-1 was found in 37% of the
clinical isolates [GenBank: EU977570] (See Additional
file 1). The other reported metallo-β-lactamases such as
blaSIM, blaIMP, blaVIM, blaGIM and other β-lactamases includ-
ing blaSHV, blaCTX-M, blaPER, were not detected in any of our
isolates.
Molecular determinants for aminoglycoside resistance
Class 1 integrons were found in 40% (33/83) of the iso-
lates. The length of the amplicons ranged between 0.75 to
2.5-kb. The 0.75-kb amplicon found in a single isolate car-
ried an aminoglycoside modifying enzyme (AME) aadB
[Genbank: EU977565]. The 1.6-kb amplicon detected in
three isolates with Type I PFGE profile, AC0047, AC0050
and AC0053 harboured aadB and aadA2 gene cassettes
[GenBank: EU977566].
The 2.3-kb amplicon found in 26 isolates carried aacA4-
catB8-aadA2 gene cassettes [GenBank: EU977568]. In this
study, 33% (28/84) of the isolates belonged to PFGE type
VII. Of these, 24% (20/84) harboured Class 1 integron
with aacA4-catB8-aadA1 variable region whereas the
remaining 9% (8/84) isolates did not harbour integron.
A 2.5-kb amplicon obtained in three clinical isolates,
AC0023, AC0024 and AC0039 carried aacC1-orfX-orfX'-
aadA1 gene cassettes [GenBank: EU977567] (Figure 2).
The integrases intI2 and intI3 were not found in any of the
isolates. The aminoglycoside resistance gene aphA6 was
found in 18% of the isolates (15/83) that exhibited differ-
ent MDR profiles [GenBank: EU977572] (See Additional
file 1).Page 4 of 10
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Plasmids were found in 66 clinical isolates. Plasmids from
strains belonging to 13 different pulsotypes were trans-
formed into E. coli JM109 and colonies were obtained
only on tetracycline containing LB plate. Though the size
of transformed plasmids (originally obtained from A. bau-
mannii isolates exhibiting various pulsotypes) in the
obtained colonies were different (which was 5–9 kb), it
was interesting to note that they all harboured tet(B) efflux
gene (See Additional file 1).
Plasmid borne quinolone resistance qnr genes (qnrA1–6,
qnrB1–6 and qnrS1–2) could not be identified in this study.
PFGE profiles of selected strainsFigure 1
PFGE profiles of selected strains. A. baumannii isolates representing various resistance profiles from different hospitals and 
different units were genotyped. Figure is the representation of PFGE fingerprints of thirty one selected isolates. Thirteen geno-
types (Group I to XIII) were identified in this study. The percentage of similarities was determined by the Dice's coefficient and 
UPGMA clustering. Major clusters were formed at the 75% similarity level. * Source abbreviations are MC (Ohio State Univer-
sity Medical Center) and CH (All central Ohio isolates derived from the State Public Health laboratory). The various ICUs in 
MC include Ross Heart hospital, James Cancer Hospital, Rhodes and Doans hospital and the Emergency Department.
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In this study, 79.5% of the nalidixic acid and ciprofloxacin
resistant isolates (66/83) (See Additional file 1) har-
boured sense mutations (Serine to Leucine) at the 83rd
and 80th positions in gyrA and parC QRDR respectively
[GenBank: EU977575 and EU977576] (See Additional
file 1). Additional sense mutations could not be detected
elsewhere in these target genes (data not shown).
To elucidate the role of active efflux [27] ciprofloxacin
accumulation studies were performed, and analysis indi-
cated that accumulation of ciprofloxacin at steady state
was higher in sensitive strains, which was 2.0 to 2.5 times
greater than the amount in MDR strains. Addition of
CCCP (25 μg/ml) resulted in the restoration of the fluo-
rescence intensity in MDR strains, eventually increasing its
level comparable to that of the sensitive strain (Figure 3).
Growth inhibition assay also supported the findings of
the CCCP mediated inhibition of ciprofloxacin and nali-
dixic acid efflux in MDR isolates (Figure 4). Addition of
CCCP drastically reduced the MIC for ciprofloxacin in 66
MDR isolates clearly indicating the role of efflux mecha-
nism in conferring quinolone resistance (See Additional
file 1).
Specific PCR assays demonstrated that 53% (44/83) of the
isolates had the transporter gene adeB [29] (See Addi-
tional file 1); response regulator adeR and its cognate
kinase adeS. Though 66 strains were quinolone resistant,
the adeB efflux gene was found in 44 isolates only, this
observation indicates that other efflux systems could be
involved in mediating quinolone resistance. Single point
mutations in adeR (Pro116→Leu) and adeS
(Thr153→Met) known to cause AdeABC constitutive
overexpression [30] were not identified in this study.
Discussion
The study presented here describes the first hospital based
outbreak of imipenem resistant A. baumannii isolates pro-
ducing the carbapenem hydrolyzing oxacillinase blaOXA-23
in central Ohio. OXA-23 producers have been identified
as sources of nosocomial outbreaks worldwide, including
the United States [1,12,13,16]. Acquired blaOXA-23 gene is
known to be located in peculiar transposon structures,
Schematic representation of different types of gene cassettes identified in the Class 1 integrons in A. baumannii strainsFigure 2
Schematic representation of different types of gene cassettes identified in the Class 1 integrons in A. baumannii 
strains. Dotted lines represent the gene cassettes, oval circles the 59-base elements. The attI recombination site is shown by 
the hatched box. Locations of the 5'CS and 3'CS of class 1 integrons and those of the primer pairs, qacEΔ1-F, Sul1B and in-F 
(5'CS), in-B (3'CS), are shown in the bottom panel. Different types of variable region were found in our collection of isolates: 
Type I: accC1-orfX-orfX'-aadA1; n = 3, Type II: aacA4-catB8-aadA1, n = 26, Type III: aadB-aadA2; n = 3 and Type IV: aadB; n = 1. 
accC1 (3-N-aminoglycoside acetyltransferase) and aadB (2'-O-adenylyltransferase) confers gentamicin resistance, aadA1 and 
aadA2 (adenyltransferase) confers resistance to spectinomycin and streptomycin, aacA4 (6'-N-acetyltransferase) confers resist-
ance to amikacin, netilmicin and tobramycin, catB8 (chloramphenicol acetyltransferase) confers resistance to chloramphenicol. 
The diagram was not drawn to scale.
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linked) [8,9,11,31]. Of note, the origin of blaOXA-23 was
recently identified as the chromosome of Acinetobacter
radioresistens, a commensal species of the human skin
[32]. In this study, 11 out of 66 imipenem-resistant iso-
lates harboured blaOXA-23 like gene. Attempts to transfer
carbapenem resistance by electroporation of plasmid
DNA from blaOXA-23 positive isolates were unsuccessful,
indicating the probable chromosomal location of this
gene.
Numerous reports on A. baumannii clinical isolates har-
bouring CHDLs OXA-58, OXA-40 and OXA-24 in the
United States reflect their emergence as important carbap-
enemases [13,14,16]; however, they could not be detected
in this set of isolates. Also, as demonstrated these A. bau-
mannii clinical isolates (79.5%) possessed the chromo-
somal-encoded oxacillinase gene blaOXA-66 that encodes aβ-lactamase known to confer carbapenemase properties
[5,6]. Multiple copies of ISAba1 are present in most iso-
lates of Acinetobacter spp. [11]. It serves an important role
as a 'mobile promoter' [33]. As evidence of this role, we
found ISAba1 immediately upstream of blaOXA-66 gene in
66 imipenem resistant isolates. More than 25 varieties of
AmpC β-lactamases that share 94% protein sequence
identity have been described for Acinetobacter spp. so far
[34]. The oxyimino-β-lactam resistance seen in these A.
baumannii strains is attributed to the presence of blaADC-25.
In this current study, gene cassettes including aacA4-catB8-
aadA1 and aacC1-orfX-orfX'-aadA1 were predominantly
Accumulation studies with ciprofloxacinFig re 3
Accumulation studies with ciprofloxacin. The fluorescence of the supernatant was measured with spectroflourimeter (LS 
55 Fluorescence Spectrometer, 120 V, Perkin-Elmer model) at an excitation 275 nm and emission 440 nm for ciprofloxacin. 
The results for six representative MDR strains, namely, AC0003, AC0007, AC0008, AC0050, AC0062, AC0089 and one sensi-
tive strain AC0030 are shown here. The graphs reflect the difference in fluorescence displayed by the bacterial cell in the pres-
ence and absence of efflux pump inhibitor CCCP. The arrow indicates the time of addition of CCCP. All experiments were 
carried out at least three times.
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in vitro analysis of growth kineticsFigure 4
in vitro analysis of growth kinetics. The ability of different MDR clinical isolates namely AC0050, AC0062, AC0089 and 
sensitive strain AC0030, to grow in the presence of different concentrations of ciprofloxacin (A), nalidixic acid (B), either alone 
or in the presence of 25 μg/ml of CCCP was monitored in LB broth using a spectrophotometer. Range of results obtained for 
duplicate experiments are shown by error bars.
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Annals of Clinical Microbiology and Antimicrobials 2009, 8:21 http://www.ann-clinmicrob.com/content/8/1/21found. Notably, so far these groups of cassettes are
reported only in two international lineages, called Euro-
pean clones I and II [35-37]. Given the very high rate of
quinolone resistance, this class is unlikely to have any
clinical role in the treatment of MDR A. baumannii in cen-
tral Ohio hospitals.
Conclusion
Despite the increased frequency of multidrug resistance in
A. baumannii in the United States, there exists a relative
paucity of information regarding antimicrobial resistance
in this Gram negative bacillus from central Ohio. The
identification of blaOXA-23 and ISAba1 associated blaOXA-66
genes in this study confirms the wide geographical distri-
bution of carbapenemases among A. baumannii as well as
their parallel appearance in outbreak strains. The experi-
ence with these MDR isolates suggested that surveillance
for multidrug resistant A. baumannii should be main-
tained and careful infection control measures and cau-
tious use of antibiotics must be promoted.
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